FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
This study did not reveal a benefit for the overall population, but addition of AAP + apalutamide (vs bicalutamide) to sRT and ADT improved PFS and MFS in the prespecified subgroup with PSA >0.5 ng/ml.
Authors
- Noah M. Hahn (ORCID: https://orcid.org/0000-0002-1016-9024)
- Dana E. Rathkopf (ORCID: https://orcid.org/0000-0002-4503-7582)
- David Johnson Einstein (ORCID: https://orcid.org/0000-0001-9163-3281)
- Robert Timothy Dess (ORCID: https://orcid.org/0000-0003-2331-3758)
- Brent Shane Rose (ORCID: https://orcid.org/0000-0002-3197-9552)
- Anthony Wong (ORCID: https://orcid.org/0000-0002-9288-061X)
- Yi An (ORCID: https://orcid.org/0000-0002-4511-4082)
- Kee-Young Shin
- Karen E. Hoffman
- Adam S. Kibel
- Amado J. Zurita
- Paul L. Nguyen
- Rana R. McKay
- James B. Yu
- Marisa A. Kollmeier
- Mary-Ellen Taplin
- Stanley L. Liauw
- Daniel E. Spratt
- Felix Y. Feng
- Russell Z. Szmulewitz
Institutions
- Brigham and Women's Hospital (US)
- Dartmouth–Hitchcock Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, San Francisco (US)
- National Foundation for Cancer Research (US)
- University Hospitals of Cleveland (US)
- Yale University (US)
- Michigan Medicine (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- European Urology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.eururo.2025.12.001
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00